Literature DB >> 10981143

Prospective trials of angiotensin receptor blockers: beyond blood pressure control.

H M Siragy1, R M Carey.   

Abstract

Mesh：

Substances：

Year:  2000        PMID： 10981143     DOI： 10.1007/s11906-000-0076-1

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN： 1522-6417            Impact factor:   5.369


× No keyword cloud information.
  7 in total

Review 1.  Action of angiotensin receptor subtypes on the renal tubules and vasculature: implications for volume homeostasis and atherosclerosis.

Authors:  C Zitnay; H M Siragy
Journal:  Miner Electrolyte Metab       Date:  1998

2.  Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial.

Authors:  J N Cohn
Journal:  Cardiology       Date:  1999       Impact factor: 1.869

Review 3.  Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation.

Authors:  S Julius
Journal:  Cardiology       Date:  1999       Impact factor: 1.869

4.  The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.

Authors:  B Dahlöf; R Devereux; U de Faire; F Fyhrquist; T Hedner; H Ibsen; S Julius; S Kjeldsen; K Kristianson; O Lederballe-Pedersen; L H Lindholm; M S Nieminen; P Omvik; S Oparil; H Wedel
Journal:  Am J Hypertens       Date:  1997-07       Impact factor: 2.689

5.  Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure.

Authors:  J N Cohn; G Tognoni; R D Glazer; D Spormann; A Hester
Journal:  J Card Fail       Date:  1999-06       Impact factor: 5.712

6.  Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan.

Authors:  K Dickstein; J Kjekshus
Journal:  Am J Cardiol       Date:  1999-02-15       Impact factor: 2.778

7.  The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.

Authors:  J Mann; S Julius
Journal:  Blood Press       Date:  1998-05       Impact factor: 2.835
  7 in total
  1 in total

1.  Gene expression profiling following maternal deprivation: involvement of the brain Renin-Angiotensin system.

Authors:  Claudia Liebl; Markus Panhuysen; Benno Pütz; Dietrich Trümbach; Wolfgang Wurst; Jan M Deussing; Marianne B Müller; Mathias V Schmidt
Journal:  Front Mol Neurosci       Date:  2009-05-14       Impact factor: 5.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.